Core C: Clinical and Biostatistic Core

这项建议的总体目标是分析健康人群中SARS-CoV-2抗体的血清转换率。 埃默里大学医院的护理人员下一年的工作，并研究适应性免疫反应 在急性感染和恢复期对SARS-CoV-2感染的保护作用。这些研究将借鉴三项 样本的主要来源，要么是通过埃默里疫苗公司的一项新的传染病方案 中心希望诊所，通过在埃默里启动的一项血清监测研究，以前收集了PBMC 和来自成人或老年捐赠者的血清样本，分别由Jorg Goronzy博士提供。我们将发展和 采用抗体结合试验和病毒中和试验相结合的方法检测 感染诱导的抗体反应的质量。此信息还将用于确定最佳 供体进行单细胞抗体表达克隆，正如我们之前所描述的那样。A最近 在我们位于埃默里疫苗中心的BSL3设施中购买10倍仪器将允许进行详细分析 急性SARS-CoV-2期间先天免疫反应和获得性免疫反应转录谱的研究 感染。拟议中的研究将为了解这种毁灭性疾病的动态提供关键的见解。 亚特兰大一家大型大都会医院的医护人员。这些努力还将产生 血清学工具，提供对SARS-CoV-2感染的体液免疫反应的了解， 并产生具有诊断和治疗潜力的人类单抗。

The over-arching goal of this proposal is to analyze SARS-CoV-2 antibody seroconversion rates in health care workers at the Emory University Hospital over the next year and to study adaptive immune responses to SARS-CoV-2 infection during acute infection and at convalescence. These studies will draw on three main sources of samples, either through an emerging infectious disease protocol at the Emory Vaccine Center Hope Clinic, through a sero-surveillance study initiated at Emory, and previously collected PBMC and serum samples from adult or elderly donors by Dr. Jorg Goronzy, respectively. We will develop and employ a combination of antibody binding assays and viral neutralization assays to test the quantity and quality of the infection-induced antibody responses. This information will also be used to identify optimal donors for single-cell antibody expression cloning, as we have previously described. A recently purchased 10x instrument in our BSL3 facility at the Emory Vaccine Center will allow for a detailed analysis of the transcriptional profiles of innate and adaptive immune responses during acute SARS-CoV-2 infection. The proposed studies will provide key insight into the dynamics of this devastating disease among health care workers at a major metropolitan hospital in Atlanta. These efforts will also generate key serological tools, provide an understanding of the humoral immune response to SARS-CoV-2 infection, and generate human monoclonal antibodies, with both diagnostic and therapeutic potential.